

1 Introduction

The rapid global spread and unique epidemiological characteristics of 2019-nCoV virus is deeply concerning.

In coordination with WHO, as it leads the development of a coordinated international response, CEPI is promoting the development of new vaccines against the emerging threat of 2019-nCoV virus.

2. Objectives and the scope of this Call

The objective of this Call for Proposals is to rapidly develop and manufacture a proven vaccine approach that can be used against the 2019-nCoV. This call aims to complement CEPI's 2019-nCoV portfolio and candidates should have large-scale manufacturing capabilities for 2019-nCoV. The organization must be willing to transfer their vaccine technology to a global network of large-scale manufacturing.

Vaccine candidates will be evaluated against several criteria to assess the utility of the product candidate and the speed with which it can be developed and tested and induce a 2019-nCoV virus-specific response. The technology will also be judged against its proven ability to be manufactured at large scale.

The suggested vaccine-technology performance will be considered towards the following guidelines:

- Speed from sequence of pathogen availability to clinical-trial testing

- Number of doses needed – to gain clinical benefit

- Scale of manufacturing

- o In the current situation CEPI will be aiming for a capacity of production of millions of doses

Criterion